Consensus United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq 16:00:00 2024-07-16 EDT 5-day change 1st Jan Change
328.2 USD +0.28% Intraday chart for United Therapeutics Corporation +1.72% +49.25%

Evolution of the average Target Price on United Therapeutics Corporation

Price target over the last 5 years

History of analyst recommendation changes

af8f1ffb5.6H9jqxRdd3dL9XVHkIaba7U8VLVjCsKRoo_MzUNhH_4.0AVQ5W0MJxQBlzY-0v6sAc1XF_MzX7fI976hmBJVXcadMRTfV2UbM36bBg~e7cc117540172da87e94e89f7008fcc3
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating MT
Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310 MT
Analyst recommendations: Albemarle, Levi Strauss & Co, On Semiconductor, Spotify, Costco... Our Logo
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating MT
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing MT
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,585,601, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $582,195, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,829,903, According to a Recent SEC Filing MT
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating MT
Oppenheimer Adjusts United Therapeutics Price Target to $400 From $375, Maintains Outperform Rating MT
United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
328.2 USD
Average target price
314.5 USD
Spread / Average Target
-4.18%
High Price Target
400 USD
Spread / Highest target
+21.88%
Low Price Target
221 USD
Spread / Lowest Target
-32.66%

Consensus detail

Consensus revision (last 18 months)

Analysts covering United Therapeutics Corporation

Wells Fargo Securities
UBS
Oppenheimer
Goldman Sachs
Leerink Partners
Wedbush
Morgan Stanley
Ladenburg Thalmann
Argus
Credit Suisse
HC Wainwright
JPMorgan Chase
Jefferies & Co.
BTIG
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Consensus United Therapeutics Corporation